HPV Entry Into Basal Epithelium
Placeholder: virus enters through microabrasions and infects basal cells.
- 2-8 wks: Incubation window (Placeholder timing note)
- Basal layer: Entry site (Placeholder location note)
- ~80%: Global prevalence (Placeholder lifetime exposure)
- 200+: HPV genotypes (Placeholder genotype count)
Viral entry mechanism
Placeholder: HPV virions access basal keratinocytes via epithelial microtrauma.
Placeholder callout: infection is usually asymptomatic and undetected.
Cytotoxic T-cell Immune Activation
Placeholder: adaptive immunity mobilizes T-cells against infected cells.
- ~1-3 mo: Response onset (Placeholder activation delay)
- CD8+ T-cell: Key cell type (Placeholder effector cell)
- IFN-γ: Cytokine signal (Placeholder signaling molecule)
- Pap smear: Detection method (Placeholder screening tool)
Immune surveillance activation
Placeholder: local immune cells detect and target infected keratinocytes.
Placeholder callout: cell-mediated immunity is the main clearance driver.
Resolution Within One To Two Years
Placeholder: the majority of HPV infections clear without intervention.
- ~90%: Clearance rate (Placeholder within 2 years)
- 8-14 mo: Median time (Placeholder clearance duration)
- Low: Recurrence risk (Placeholder reinfection note)
- Routine: Follow-up (Placeholder screening interval)
Natural resolution pathway
Placeholder: cleared infections leave normal epithelial architecture intact.
Placeholder callout: most patients need no further treatment.
High-Risk HPV Genomic Integration
Placeholder: high-risk types evade clearance and integrate into the genome.
- ~10%: Persistence rate (Placeholder high-risk cases)
- HPV16/18: Key genotypes (Placeholder oncogenic types)
- E6/E7: Oncoproteins (Placeholder viral proteins)
- Host genome: Integration site (Placeholder mechanism note)
Immune evasion and integration
Placeholder: persistent high-risk HPV disrupts tumor suppressor pathways.
Placeholder callout: persistence beyond 2 years raises dysplasia risk.
Progressive Cervical Dysplasia Development
Placeholder: abnormal cell layers accumulate toward precancerous change.
- CIN 1-3: CIN grading (Placeholder severity scale)
- 5-10 yrs: Progression time (Placeholder to cancer)
- Recommended: Colposcopy (Placeholder referral note)
- CIN1 often: Reversibility (Placeholder regression note)
Dysplastic progression staging
Placeholder: disordered epithelial layers replace normal stratification over time.
Placeholder callout: early detection allows treatment before invasion.